Scarica l'app Stockscreener
36.17
2.64%
0.93
Dopo l'orario di chiusura:
36.88
0.71
+1.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$35.24
Aprire:
$35.71
Volume 24 ore:
974.26K
Relative Volume:
0.77
Capitalizzazione di mercato:
$2.12B
Reddito:
$238.11M
Utile/perdita netta:
$-31.45M
Rapporto P/E:
-57.10
EPS:
-0.6334
Flusso di cassa netto:
$7.66M
1 W Prestazione:
+0.00%
1M Prestazione:
-18.22%
6M Prestazione:
-2.85%
1 anno Prestazione:
+113.14%
Intervallo 1D:
$35.56
$36.84
Intervallo di 1 settimana:
$34.11
$36.84
Portata 52W:
$16.65
$52.91
Axogen Inc Stock (AXGN) Company Profile
Nome
Axogen Inc
Settore
Industria
Telefono
(386) 462-6817
Indirizzo
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
36.17 | 2.12B | 238.11M | -31.45M | 7.66M | -0.6334 |
ABT
Abbott Laboratories
|
102.45 | 177.28B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.63 | 121.04B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
304.40 | 116.76B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.58 | 66.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.29 | 50.89B | 6.30B | 1.07B | 1.09B | 1.8406 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-12 | Iniziato | BofA Securities | Buy |
| 2026-10-07 | Iniziato | Barclays | Overweight |
| 2026-08-26 | Iniziato | Truist | Buy |
| 2026-02-19 | Iniziato | Wells Fargo | Overweight |
| 2025-12-01 | Iniziato | Mizuho | Outperform |
| 2025-03-17 | Iniziato | Lake Street | Buy |
| 2024-07-01 | Iniziato | Raymond James | Outperform |
| 2022-11-11 | Ripresa | Jefferies | Buy |
| 2022-05-09 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | Guggenheim | Buy |
| 2020-06-16 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-05-07 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-08-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | Iniziato | Canaccord Genuity | Buy |
| 2018-03-02 | Reiterato | Lake Street | Buy |
| 2018-01-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2017-11-30 | Iniziato | Jefferies | Buy |
| 2017-11-21 | Reiterato | Lake Street | Buy |
| 2017-07-31 | Iniziato | Leerink Partners | Outperform |
| 2017-06-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-06 | Iniziato | ROTH Capital | Buy |
| 2016-11-22 | Aggiornamento | Lake Street | Hold → Buy |
| 2016-11-07 | Reiterato | Wedbush | Outperform |
| 2016-11-03 | Downgrade | Lake Street | Buy → Hold |
| 2016-08-04 | Reiterato | Wedbush | Outperform |
| 2014-05-14 | Iniziato | Dawson James | Buy |
| 2013-10-31 | Reiterato | Ladenburg Thalmann | Buy |
Mostra tutto
Axogen Inc Borsa (AXGN) Ultime notizie
GMED or AXGN: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN) - Zacks Investment Research
A passive stake above 5% in Axogen (AXGN) is held through advisory clients. - Stock Titan
AXGN | Axogen, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Axogen, Inc.Common Stock (Nasdaq:AXGN) Stock Quote - The Chronicle-Journal
Axogen deepens nerve repair portfolio through $200m BioCircuit takeover - Yahoo Finance
Axogen announces pricing of public offering - medicalbuyer.co.in
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com Australia
Axogen Inc (AXGN) Shares Fall 11.5% -- What GF Score of 64 Tells Investors - GuruFocus
AXGN 424B FilingsAxogen Inc SEC 424B - Stock Titan
Axogen To Acquire BioCircuit Technologies For $200 Million To Add Sutureless Nerve Repair Platform - Pulse 2.0
Why Is Axogen Stock Tumbling Today?Axogen (NASDAQ:AXGN) - Benzinga
Axogen to buy BioCircuit Technologies for $200M - medtechdive.com
Axogen Announces $200 Million Acquisition of BioCircuit Technologies Alongside $42.50 Per Share Stock Offering - Kalkine Media
Axogen to acquire Biocircuit for $200M - BioWorld News
2 Medical-Device Stocks Lighting Up the Options Pits - schaeffersresearch.com
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com South Africa
Axogen stock falls as $208.7M offering dilutes shareholders By Investing.com - Investing.com Australia
Axogen stock falls as $208.7M offering dilutes shareholders - investing.com
Why is Axogen stock sliding today? By Investing.com - Investing.com South Africa
Axogen stock falls as $208.7M offering dilutes shareholders - Investing.com
Axogen Prices $208.7 Million Stock Offering to Fund BioCircuit Acquisition - citybiz
Axogen to Acquire BioCircuit Technologies in $200 Million Nerve Repair Deal - citybiz
Why is Axogen stock sliding today? By Investing.com - Investing.com Canada
Why is Axogen stock sliding today? - investing.com
Axogen acquires BioCircuit Technologies for $200 million - grafa.com
Axogen Announces Pricing Of $208.7 Million Public Offering Of Common Stock - TradingView
AxoGen to Acquire BioCircuit, Expanding Nerve Repair Portfolio - TipRanks
Axogen prices $208.7 million stock offering at $42.50 per share - investing.com
AXGN Looks 171.8% Overvalued on GF Value™ - GuruFocus
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com India
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com Canada
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com India
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - manilatimes.net
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com Canada
Axogen Prices $208.7 Million Public Offering of Common Stock to Help Fund BioCircuit Acquisition - Quiver Quantitative
AXGN: Acquisition of a pioneering sutureless nerve repair device is expected to drive growth and innovation - TradingView
Axogen to acquire BioCircuit for $200M, adds nerve repair device - Investing.com UK
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies - GlobeNewswire
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com South Africa
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - globenewswire.com
Nerve repair without stitches is at the center of Axogen’s $200 million deal - Stock Titan
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - Yahoo Finance
Axogen to Acquire BioCircuit Technologies for $200 Million - Yahoo Finance
The first FDA-cleared device to repair cut nerves without stitches is now part of Axogen. - Stock Titan
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - The Manila Times
Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for approximately $200 million. - marketscreener.com
Understanding the Setup: (AXGN) and Scalable Risk - Stock Traders Daily
Axogen Director Tyndall Joseph A. Disposes of 3,500 Shares at $49.70 Each - Kalkine Media
Axogen Inc Azioni (AXGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axogen Inc Azioni (AXGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| JOSEPH A TYNDALL | Director |
Sep 02 '26 |
Proposed Sale |
49.88 |
3,500 |
174,580 |
0 |
| Wendell Amy McBride | Director |
Aug 11 '26 |
Option Exercise |
14.85 |
13,353 |
198,292 |
121,329 |
| Wendell Amy McBride | Director |
Aug 11 '26 |
Sale |
48.42 |
13,353 |
646,592 |
107,976 |
| AMY MCBRIDE-WENDELL | Director |
Aug 11 '26 |
Proposed Sale |
48.22 |
13,353 |
643,882 |
0 |
| Began Marc A | EVP & General Counsel |
Aug 10 '26 |
Sale |
47.34 |
67,500 |
3,195,788 |
50,135 |
| MARC BEGAN | Officer |
Aug 10 '26 |
Proposed Sale |
46.43 |
67,500 |
3,134,025 |
0 |
| Began Marc A | EVP & General Counsel |
Aug 10 '26 |
Option Exercise |
8.16 |
67,500 |
550,800 |
117,635 |
| KATHY WEILER | Director |
Aug 07 '26 |
Proposed Sale |
44.35 |
14,150 |
627,552 |
0 |
| Weiler Kathy Johnson | Director |
Aug 07 '26 |
Sale |
45.30 |
14,150 |
640,967 |
0 |
| Wendell Amy McBride | Director |
Jun 19 '26 |
Option Exercise |
0.00 |
14,150 |
0 |
107,976 |
1.70%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):